Monument Therapeutics Announces New Advisory Appointments to Advance Schizophrenia Treatment
Portfolio - People | Nov 19, 2024 | Catapult Ventures Group
Monument Therapeutics, a company specializing in precision neuroscience, has expanded its Scientific Advisory Board with the appointments of Dr. Mark Treherne, Dr. Stephen Brannan, and Dr. Jeff Baker, aiming to advance its schizophrenia program. Dr. Treherne, with over three decades of experience, will chair the board. Dr. Brannan and Dr. Baker bring extensive backgrounds in neuroscience drug development, bolstering the clinical advancement of Monument's drug MT1988 for Cognitive Impairment Associated with Schizophrenia (CIAS). This strategic enhancement underscores Monument's commitment to addressing unmet needs in schizophrenia treatment and aligns with broader innovation goals. The appointments are expected to significantly contribute to Monument's leadership in the therapeutic landscape for serious CNS disorders.
Sectors
- Biotechnology
- Pharmaceuticals
Geography
- United Kingdom – Monument Therapeutics is based in Manchester, England, denoting its primary operational geography.
Industry
- Biotechnology – The development of therapeutic treatments for central nervous system disorders falls within the biotechnology sector, where advanced research and innovation are key to addressing unmet medical needs.
- Pharmaceuticals – Monument Therapeutics is involved in the development of pharmaceutical drugs, specifically targeting schizophrenia, a core activity within the pharmaceutical industry.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Monument Therapeutics | Target Company | Company | A precision-neuroscience company focused on developing innovative treatments for serious CNS disorders. |
| Dr. Mark Treherne | Chairperson of Scientific Advisory Board | Person | A research scientist with over 30 years of experience in neuroscience and drug discovery. |
| Dr. Stephen Brannan | Advisory Board Member | Person | A neuroscience drug development expert with a track record in advancing treatments for severe mental health conditions. |
| Dr. Jeff Baker | Advisory Board Member | Person | An experienced leader in CNS drug development, focusing on cognitive and psychiatric conditions. |
| Catapult Ventures Group | Private Equity Firm | Company | Investment firm backing Monument Therapeutics. |